CHEMISTRY A European Journal



Accepted Article

Title: Hydroaminoalkylation of Allylsilanes and a One-Pot Procedure for the Synthesis of 1,5-Benzoazasilepines

Authors: Sven Doye, Lars H. Lühning, Julia Strehl, and Marc Schmidtmann

This manuscript has been accepted after peer review and appears as an Accepted Article online prior to editing, proofing, and formal publication of the final Version of Record (VoR). This work is currently citable by using the Digital Object Identifier (DOI) given below. The VoR will be published online in Early View as soon as possible and may be different to this Accepted Article as a result of editing. Readers should obtain the VoR from the journal website shown below when it is published to ensure accuracy of information. The authors are responsible for the content of this Accepted Article.

To be cited as: Chem. Eur. J. 10.1002/chem.201605923

Link to VoR: http://dx.doi.org/10.1002/chem.201605923

Supported by ACES



10.1002/chem.201605923

Hydroaminoalkylation of Allylsilanes and a One-Pot Procedure for the Synthesis of 1,5-Benzoazasilepines

Lars H. Lühning, Julia Strehl, Marc Schmidtmann, and Sven Doye*[a]

Abstract: Allylsilanes undergo highly regioselective intermolecular alkene hydroaminoalkylation with secondary amines in the presence of a titanium mono(formamidinate) catalyst. Corresponding reactions of a suitable allyl(2-bromophenyl)silane which exclusively deliver the branched hydroaminoalkylation products combined with a subsequent Buchwald-Hartwig amination result in the development of an elegant one-pot procedure for the synthesis of literature-unknown silicon analogues of 1,5-benzodiazepines, so-called 1,5-benzoazasilepines.

Introduction

Until the early 1960's, organosilicon compounds were widely regarded as a biologically ineffective class of chemical substances.^[1] However, after this opinion had been changed through the investigation of the unusual high toxicity of silatranes by Voronkov et al.,^[2] organosilicon chemistry became more and more popular in the pharmaceutical sector during the past decades.^[3] While one method for the development of new drugs is the high-throughput synthesis and high-throughput screening approach, an alternative possibility is the sila-substitution (Si/C exchange) in known drug scaffolds.^[3,4] The feasibility of the latter approach which was pioneered by the Tacke-group,[4a-c,e-k] has strongly been underlined by a large number of examples in which sila-substitution significantly affects the features of a drug. For example, the different geometry and bond lengths of Si-C (187 pm) and C-C bonds (154 pm) as well as the different pK_a values of silanols ($pK_{a(DMSO)}$ of Ph₃SiOH = 16.6) compared to alcohols (p $K_{a(DMSO)}$ of Ph₃COH = 17.0) are important aspects which may favor sila-substituted drugs over the corresponding carbon species.^[3] In addition, silicon analogues are generally more lipophilic, which makes them less prone to hepatic metabolism. On the other hand, the increase of the lipophilicity also influences the ability to cross the blood/brain barrier.[4b] The latter effect should be even more significant when, for example, a nitrogen atom is replaced by a silicon atom. Therefore, pharmaceuticals interacting with the central nervous system, especially with the brain, may benefit from the introduction of a silicon atom into their structures. However, relatively little attention has been paid to the exchange of nitrogen with silicon in known drug scaffolds.

Benzodiazepines are able to bind to the inhibitory important GABA receptors (GABA: y-aminobutyric acid) of the central

 [a] L. H. Lühning, J. Strehl, Dr. M. Schmidtmann, Prof. Dr. S. Doye Institut für Chemie Universität Oldenburg Carl-von-Ossietzky-Straße 9-11 26111 Oldenburg (Germany) E-Mail: doye@uni-oldenburg.de

Supporting information for this article is given via a link at the end of the document.

nervous system and as a result, they show sedative, muscle relaxant, anticonvulsant, and anxiolytic effects.^[5,6] Very recently, we were able to develop a new one-pot procedure for the synthesis of 1,5-benzodiazepines.^[7] The corresponding reaction sequence includes an initial highly regioselective titaniumcatalyzed intermolecular hydroaminoalkylation,^[8,9] which takes place by the addition of an α -C(sp³)-H bond of an Nmethylaniline across a C-C double bond of an N-allyl-2bromoaniline, and a subsequent intramolecular Buchwald-Hartwig amination (Scheme 1, path A).^[10] In continuation of this study and inspired by the fact that until now, unsaturated silanes have not been used as substrates for titanium-catalyzed hydroaminoalkylation reactions, we recently decided to investigate the scope of allylsilanes as starting materials for corresponding transformations. However, in this context it must be noted that Schafer et al. already achieved the hydroaminoalkylation of allyltrimethylsilane with N-methylaniline in the presence of a tantalum catalyst.^[11] Interestingly, by choosing allyl(2-bromophenyl)silanes as starting materials, the literature-unknown silicon analogues of 1,5-benzodiazepines, so-called 1,5-benzoazasilepines (Scheme 1, path B), should be accessible by a one-pot procedure that is similar to our 1,5benzodiazepines synthesis. In this context, it has to be mentioned that Voronkov et al.^[12] as well as Tacke et al.^[13] already synthesized closely related 1,4-azasilepanes, which lack the benzo-annulation of the seven-membered ring, by using alternative strategies and very recently, a lot of effort has been spent on the development of new pathways for the synthesis of enantioselective closely related 1,5benzothiazepines.^[14] In addition, the synthesis of fullv unsaturated 1-benzosilepines has also been described before.^[15]



Scheme 1. One-pot procedures for the preparation of 1,5-benzodiazepines and 1,5-benzoazasilepines.

Results and Discussion

Initially, a series of titanium^[9] and tantalum catalysts,^[16] that had already been identified to be active in hydroaminoalkylation reactions,^[8] were used for a brief catalyst screening (Figure 1, Table 1) in which allyldimethylphenylsilane (1a) was tried to react with N-methylaniline (2). First of all, it was recognized that Ti(NMe₂)₄ as well the aminopyridinato titanium catalysts I and II do not show any catalytic activity at 140 °C (Table 1, entries 1-3), while at the same temperature, complexes III, IV, Ind₂TiMe₂ (Ind = η^{5} -indenyl), and Ta(NMe₂)₅ do catalyze the desired reaction (Table 1, entries 4, 5, 8, and 10). Among the active catalysts, titanium mono(formamidinate) complex IV initially synthesized by Eisen et al.^[17] gave the best result which led to the formation of the desired branched hydroaminoalkylation product 3a in excellent yield of 90 % (Table 1, entry 5). Inspired by the wellestablished fact, that hydroaminoalkylation reactions performed with the catalyst Ind₂TiMe₂ often give improved vields at lower temperatures.^[9d] we also performed selected reactions at lower temperatures. However, while a significantly improved vield of 71 % was indeed obtained with the catalyst Ind₂TiMe₂ at 105 °C (compared to 10 % at 140 °C, Table 1, entries 8 and 9), the catalytic performance of IV could not be improved, neither at lower nor at higher temperatures (Table 1, entries 5-7). Interestingly, and in contrast to corresponding reactions of styrenes,^[9d,k] detectable amounts of the linear hydroaminoalkylation product were not formed from allylsilane 1a in the presence of catalysts IV or Ind₂TiMe₂. Although corresponding regioselectivities were also obtained with catalysts III or Ta(NMe2)5, the better yield of 90 % obtained with IV (Table 1, entry 5) led to the decision to run all further experiments with formamidinate catalyst IV at 140 °C.



Figure 1. Titanium catalysts for hydroaminoalkylation reactions of alkenes.

To investigate the scope of the hydroaminoalkylation of allylsilanes, a large number of *ortho-*, *meta-*, and *para*substituted *N*-methylanilines were then reacted with allyldimethylphenylsilane (**1a**), allyltrimethylsilane (**1b**), or allyltriphenylsilane (**1c**) under the conditions of Table 1, entry 5 using 10 mol% of catalyst **IV**. During this study which is summarized in Table 2, it was first recognized that the reactivity of the allylsilane is not significantly influenced by the nature of the substituents bound to the silicon center and correspondingly, all three allylsilanes **1a-1c** gave comparable results. On the

hand, sterically demanding other ortho-substituted methylanilines were found to be challenging substrates and as a result, slightly reduced yields between 59 % and 74 % were obtained with N-methyl-ortho-toluidine. In addition, a successful reaction of N-methyl-ortho-chloroaniline could only be achieved with sterically less demanding allylsilane 1b but even in this case, the product 5b could only be isolated in a disappointing yield of 6 %. With regard to the results obtained with meta- and para-substituted N-methylanilines, it becomes clear that besides alkyl substitution, the presence of fluoro, chloro, and bromo substituents is also tolerated. The excellent yields in which the chloro- and bromo-substituted products 8a-8c, 9a-9c, 13a-13c, and 14a-14c (76-96 %) were formed deserve particular attention because bromo and chloro substituents offer various possibilities for further functionalization.^[18] In addition, it should be mentioned that in former studies, halogenated substrates often gave poor results in hydroaminoalkylation chemistry.^[9d,g,h] Since the same is true for reactions of the electron acceptor-substituted starting material N-methyl-para-trifluoromethylaniline, it was not surprising to find that under the reaction conditions, this substrate does not react at all with the allylsilanes 1a-1c. However, on the other hand, the hydroaminoalkylation products 16a-16c which possess a pharmacologically relevant trifluoromethoxy substituent could be isolated in excellent yields between 83 % and 87 %. This result is in good agreement with the performance of additional ether-substituted N-methylanilines which led to the formation of the corresponding methoxy- or phenoxy-substituted products 15a-15c and 17a-17c in 74-87 % yield. Finally, it was even possible to isolate the thiomethyl ether products 18a-18c in good yields of 74-87 %.

 Table
 1. Catalyst screening for the hydroaminoalkylation of allyldimethylphenylsilane (1a) with N-methylaniline (2).^[a]

	Si, +	HN -	10 mol% catalyst toluene <i>T</i> , 24 h	► C	H N
6	1a	2	·		3a
	Entry	Catalyst		<i>T</i> [°C]	Yield [%] ^[b]
	1	Ti(NMe ₂) ₄		140	0
	2	I		140	0
	3	II		140	0
	4	ш		140	71
	5	IV		140	90
	6	IV		120	65
	7	IV		160	78
	8	Ind ₂ TiMe ₂		140	10
	9	Ind ₂ TiMe ₂		105	71
	10	Ta(NMe ₂) ₅		140	70

[a] Reaction conditions: allyldimethylphenylsilane (**1a**, 2.2 mmol, 388 mg), *N*-methylaniline (**2**, 2.0 mmol, 214 mg), catalyst (0.2 mmol, 10 mol%), toluene (1 mL), *T*, 24 h. [b] Isolated yield.

WILEY-VCH

Table 2. Hydroaminoalkylation of allylsilanes with various N-methylanilines.[a]



[a] Reaction conditions: silane (2.2 mmol), *N*-methylaniline (2.0 mmol), **IV** (0.2 mmol, 109 mg, 10 mol%), toluene (1 mL), 140 °C, 24 h. Yields refer to isolated yields.

Additional attempts to achieve corresponding reactions of allyldimethylphenylsilane (1a) with dialkylamines turned out to be successful under identical reaction conditions with Nmethylcyclohexylamine and N-methylbenzylamine (Table 3). However, the generally reduced reactivity of dialkylamines in hydroaminoalkylation reactions^[8,9,11,16] is in good agreement with the reduced yield of 50 % in which product 19 was obtained from 1a and N-methylcyclohexylamine (Table 3, entry 1). On the other hand, a simple prolongation of the reaction time from 24 h to 48 h raised the yield to 76 % (Table 3, entry 2). The reaction of N-methylbenzylamine with 1a gave access to product 20 in good yield of 70 % (Table 3, entry 3) but in this case, the alkylation of the amine took place selectively at the benzylic position and not at the usually preferred methyl group. The latter observation has been made before during closely related hydroaminoalkylation studies with this substrate.[9g,j]

Table 3. Hydroaminoalkylation of allyldimethylphenylsilane (1a) with dialkylamines. $\ensuremath{^{[a]}}$

Si 1a	· +	${igstackinet^{H}_{N_{N}}}{R^2}$	10 mol% IV toluene 140 °C, t	$Si H N R^2$ R^1
Entry	<i>t</i> [h]	R^1	R ²	Yield [%] ^[b]
1	24	Н	Су	50 (19)
2	48	Н	Су	76 (19)
3	24	Ph	Me	70 (20)

[a] Reaction conditions: allyldimethylphenylsilane (1a, 2.2 mmol, 388 mg), dialkylamine (2.0 mmol), IV (0.2 mmol, 109 mg, 10 mol%), toluene (1 mL), 140 °C, t. [b] Isolated yield.

As mentioned above, a reasonable synthetic approach towards 1,5-benzoazasilepines, which represent the silicon analogues of pharmaceutically relevant 1,5-benzodiazepines, consists of an initial hydroaminoalkylation of allyl(2-bromophenyl)silanes and a subsequent intramolecular Buchwald-Hartwig amination (Scheme 1, path b). Correspondingly, we next focused on the hydroaminoalkylation of allyl(2-bromophenyl)dimethylsilane (**21**) which to our delight, took place smoothly with *N*-methylaniline (**2**) under standard conditions to give the desired product **22** in excellent yield of 91 % (Scheme 2).



Scheme 2. Hydroaminoalkylation of allyl(2-bromophenyl)dimethylsilane (21).

With key-intermediate **22** in hand, a brief ligand screening for the Buchwald-Hartwig amination was then conducted using

WILEY-VCH

Pd₂(dba)₃ (dba = dibenzylideneacetone) as the palladium source and sodium *tert*-butoxide as a base (Table 4). Although *rac*-BINAP had already been identified to be a good ligand for the corresponding formation of 1,5-benzodiazepines,^[7] the cyclization of **22** which delivered the 1,5-benzoazasilepine **23** only took place with a moderate yield of 64 % in the presence of this ligand (Table 4, entry 1). While even worse yields were obtained with the ligands JohnPhos and dppf (Table 4, entries 2 and 3), the use of the biphenyl-based ligands XPhos or RuPhos finally gave access to the desired product **23** in significantly improved yields of 82 % and 93 %, respectively (Table 4, entries 4 and 5).

Table 4. Ligand screening for the intramolecular Buchwald-Hartwig amination of hydroaminoalkylation product $\mathbf{22}^{[a]}$



[a] Reaction conditions: silane (1.0 mmol, 362 mg), $Pd_2(dba)_3$ (0.025 mmol, 23 mg, 2.5 mol%), ligand (0.1 mmol, 10 mol%), NaO'Bu (1.5 mmol, 144 mg), toluene (3 mL), 110 °C, 24 h. [b] Isolated yield.

Because overall the best result of the intramolecular Buchwald-Hartwig amination of 22 was obtained with RuPhos, this ligand was then used for the finally planned development of a one-pot procedure for the synthesis of 1,5-benzoazasilepines from allyl(2-bromophenyl)silanes (Table 5). For that purpose, a hydroaminoalkylation reaction mixture of allylsilane 21 and Nmethylaniline (1) in toluene was initially heated to 140 °C for 24 h in the presence of 10 mol% of catalyst IV. Afterwards, 2.5 mol% Pd₂(dba)₃, 7 mol% RuPhos, sodium tert-butoxide and additional toluene were added and the resulting reaction mixture was heated to 110 °C for additional 24 h. The yield of 83 % in which 1,5-benzoazasilepine 23 was obtained after chromatographic purification (Table 5, entry 1) again underlines the well-established fact that the Buchwald-Hartwig amination presence of the reagents used tolerates the in hydroaminoalkylation reactions.^[7] However, the sensitivity of the titanium catalyst against alcohols and carbonyl compounds rules out the possibility to develop a related one-pot protocol in which both the titanium and the palladium catalyst are added to the flask at the same time. To finally investigate the scope of the one-pot procedure, we then reacted additional ortho-, meta-, and para-substituted N-methylanilines with allylsilane 21. As expected and in good agreement with the results obtained for the hydroaminoalkylation of simple allylsilanes presented in Table 2, it was found that para- or meta-substituted Nmethylanilines undergo smooth reaction to give the desired 1,5benzoazasilepines in good yields between 66 % and 84 % (Table 5, entries 3-11). On the other hand, it is worth mentioning that even the sterically demanding ortho-methyl-substituted 1,5benzoazasilepine 24 could be isolated in a moderate yield of 47 % (Table 5, entry 2). However, overall, the results presented in Table 5 clearly show that besides alkyl and ether substitution, the one-pot procedure also tolerates the presence of pharmacologically promising fluoro, chloro, trifluoromethyl, and thioether substituents. Finally, confirmation of the successful synthesis of the 1,5-benzoazasilepines could be achieved by a single crystal X-ray analysis of the para-methyl-substituted product 26 which is shown in Figure 2.[19]

Table 5. Scope of the one-pot procedure for the synthesis of 1,5-benzoazasilepines. $^{\left[a\right] }$



[a] Reaction conditions: 1) silane (23, 2.2 mmol, 562 mg), *N*-methylaniline (2.0 mmol), *IV* (0.2 mmol, 109 mg, 10 mol%), toluene (1 mL), 140 °C, 24 h. 2) Pd₂(dba)₃ (0.05 mmol, 46 mg, 2.5 mol%), RuPhos (0.14 mmol, 66 mg, 7 mol%), NaO'Bu (3.0 mmol, 288 mg), toluene (5 mL), 110 °C, 24 h [b] Isolated yield.

Conclusions

In summary, we have presented the first examples of titaniumcatalyzed hydroaminoalkylation reactions of allylsilanes. Although a number of different titanium complexes were found to be competent catalysts for this challenging transformation, best results were obtained with a titanium mono(formamidinate) catalyst initially synthesized by the Eisen group. Based on the finding that allylsilanes are exclusively converted to branched hydroaminoalkylation products, it was also possible to develop a one-pot procedure for the synthesis of 1,5-benzoazasilepines. The corresponding reaction sequence includes an initial hydroaminoalkylation of an allyl(2-bromophenyl)silane and a subsequent intramolecular Buchwald-Hartwig amination. Finally, it is worth mentioning that very recently, we found that vinyl silanes can also be used for closely related synthetic procedures. However, the corresponding results will be published separately in due course.^[20]



Figure 2. Single crystal X-ray structure of 1,5-benzoazasilepine **26**,^[19] ellipsoid representation at the 50 % probability level, hydrogen atoms are omitted for clarity. Selected bond length [Å] and angles [°]: Si1-C12 1.872 (2), Si1-C11 1.858 (3), Si1-C6 1.857 (2), Si1-C7 1.874 (2), C7-C8 1.540 (3), C8-C9 1.527 (3), C8-C10 1.523 (3), N1-C1 1.426 (3), N1-C9 1.464 (3), C12-Si1-C11 109.53 (15), C11-Si1-C7 111.16 (13), C12-Si1-C7 107.87 (11), C5-C6-Si1 123.41 (16), C12-C6-Si1 119.55 (15), C6-Si1-C7 109.87 (10), C13-N1-C9 121.15 (16), C13-N1-C9 1121.23 (16), C1-N1-C9 116.96 (17), C1-N1-C9 116.96(17), C7-C8-C9 112.23 (17), C7-C8-C10 110.60 (18), C9-C8-C10 110.51 (19).

Experimental Section

General: Unless otherwise noted, all reactions were performed under an inert atmosphere of nitrogen in oven-dried Schlenk tubes (Duran glassware, 100 mL, $\emptyset = 30$ mm) equipped with Teflon[®] stopcocks and magnetic stirring bars (15 × 4.5 mm). Toluene was purified by distillation from sodium wire and degassed. Catalyst **IV**,^[17] the *N*-methylanilines, and the allylsilanes were synthesized according to literature procedures.^[21] Prior to use, all substrates were distilled or recrystallized and degassed. Catalyst **IV**, the *N*-allylsilanes, the *N*-methylanilines, and toluene were stored in a nitrogen-filled glove box (M. Braun, Unilab). All other chemicals were purchased from commercial sources and were used without further purification. For flash chromatography, silica gel

WILEY-VCH

from GRACE Davison (particle size 0.037-0.063 mm) was used. Light petroleum ether (b.p. 40-60 °C, PE), tert-butyl methyl ether (MTBE), CH₂Cl₂, and EtOAc used for flash chromatography were distilled prior to use. For thin layer chromatography, silica on TLC aluminum foils with fluorescent indicator 254 nm from Fluka were used. The substances were detected with UV light or iodine. All products that have already been reported in the literature were identified by comparison of the obtained ¹H NMR and ¹³C NMR spectra with those reported in the literature. New compounds were additionally characterized by infrared (IR) spectroscopy, GC-MS, high resolution mass spectrometry (HRMS) and ²⁹Si NMR spectroscopy. NMR spectra were recorded on the following spectrometers: Bruker Fourier 300, Bruker Avance DRX 500, or Bruker Avance III, 500 MHz. All ¹H NMR spectra are reported in δ units (ppm) relative to the signal of CDCI₃ at 7.26 ppm. J values are given in Hz. All ¹³C NMR spectra are reported in δ units (ppm) relative to the central line of the triplet for CDCl₃ at 77.0 ppm. ²⁹Si NMR spectra are reported in δ units (ppm) relative to the external standard Me₂SiHCl (δ = 11.1 ppm) in relation to SiMe₄ (δ = 0.0 ppm). Infrared spectra were recorded on a Bruker Vector 22 spectrometer or a Bruker Tensor 27 spectrometer (ATR). GC-MS analyses were performed on a Thermo Finnigan Focus gas chromatograph equipped with a DSQ mass detector and Agilent DB-5 column (length: 30 m, inner diameter: 0.32 mm, film thickness: 0.25 µm (94%-methyl)-(5%-phenyl)-(1%-vinyl)polysiloxan). GC analyses were performed on a Shimadzu GC-2010 gas chromatograph equipped with a flame ionization detector. High resolution mass spectra (HRMS) were recorded on a Waters Q-TOF Premier spectrometer in EI or ESI mode (ESI+, TOF).

General Procedure for the Hydroaminoalkylation of Allylsilanes, as Exemplified by the Reaction of Allyldimethylphenylsilane (1a) with N-Methylaniline (2): An oven-dried Schlenk tube equipped with a Teflon stopcock and a magnetic stirring bar was transferred into a nitrogen-filled glovebox and charged with catalyst IV (109 mg, 0.2 mmol, 10 mol%) and toluene (0.5 mL). Afterwards, N-methylaniline (2, 214 mg, 2.0 mmol), allyldimethylphenylsilane (1a, 388 mg, 2.2 mmol), and toluene (0.5 mL) were added and the mixture was heated to 140 °C for 24 hours. After the reaction mixture had been cooled to room temperature, the crude product was purified by flash chromatography (SiO2, PE/MTBE, 40:1) to give N-(2-methyl-3-(dimethyl(phenyl)silyl)propyl)aniline (3a, 509 mg, 1.80 mmol, 90 %) as a colorless oil. $R_{\rm f}$ = 0.17 (SiO₂, PE/MTBE, 40:1). ¹H NMR (500 MHz, CDCl₃): δ = 7.57-7.47 (m, 2 H), 7.38-7.32 (m, 3 H), 7.16-7.09 (m, 2 H), 6.65 (tt, J = 0.9 Hz, J = 7.3 Hz, 1 H), 6.50 (dd, J = 0.9 Hz, J = 8.4 Hz, 2 H), 3.65 (br. s, 1 H), 2.96 (dd, J = 6.0 Hz, J = 12.3 Hz, 1 H), 2.84 (dd, J = 7.2 Hz, J = 12.3 Hz, 1 H), 1.95-1.84 (m, 1 H), 0.99 (dd, J = 4.6 Hz, J = 14.8 Hz, 1 H), 0.96 (d, J = 6.6 Hz, 3 H), 0.70 (dd, J = 8.9 Hz, J = 14.8 Hz, 1 H), 0.31 (s, 6 H) ppm. ¹³C{¹H} NMR (125 MHz, DEPT, CDCl₃): δ = 148.4 (C), 139.5 (C), 133.5 (CH), 129.2 (CH), 128.9 (CH), 127.8 (CH), 116.9 (CH), 112.6 (CH), 53.1 (CH₂), 29.5 (CH), 21.9 (CH₂), 21.0 (CH₃), –1.9 (CH₃), –2.3 (CH₃) ppm. $^{29}Si\{^{1}H\}$ NMR (99.4 MHz, INEPT, CDCl₃): δ = -3.6 ppm. GC/MS (EI, 70 eV): m/z (%) = 283 (3) [M]+, 135 (33) [C₈H₁₁Si]⁺, 106 (100) [C₇H₈N]⁺, 77 (10) [C₆H₅]⁺. HRMS (EI): calcd. (C₁₈H₂₅NSi) 283.1751, found 283.1750 [M]⁺. IR (ATR, neat): λ^{-1} = 3417, 3066, 2955, 1602, 1505, 1427, 1320, 1249, 1179, 1111, 829, 791, 746, 690 cm⁻¹.

General Procedure for the One-Pot Synthesis of 1,5-Benzoazasilepines, as Exemplified by the Synthesis of Product 26: An oven-dried Schlenk tube equipped with a Teflon stopcock and a magnetic stirring bar was transferred into a nitrogen-filled glovebox and charged with catalyst **IV** (109 mg, 0.2 mmol, 10 mol%) and toluene (0.5 mL). Afterwards, 4,*N*-dimethylaniline (242 mg, 2.0 mmol), allyl(2bromophenyl)dimethylsilane (**21**, 562 mg, 2.2 mmol), and toluene (0.5 mL) were added. After the mixture had been heated to 140 °C for 24 hours, the Schlenk tube was cooled to room temperature and transferred back into a nitrogen-filled glovebox. Then Pd₂(dba)₃ (46 mg, 0.05 mmol, 2.5 mol%), RuPhos (66 mg, 0.1 mmol, 7 mol%), NaO'Bu (288 mg, 3.0

mmol), and toluene (5 mL) were added. After heating the mixture to 110 °C for additional 24 hours, the crude product was purified by flash chromatography (SiO₂, PE) to give 1,5-benzoazasilepine 26 (480 mg, 1.62 mmol, 81 %) as a colorless solid. Rf = 0.28 (SiO₂, PE). ¹H NMR (500 MHz, CDCl₃): δ = 7.56 (dd, J = 1.5 Hz, J = 7.3 Hz, 1 H), 7.36 (dt, J = 1.5 Hz, J = 7.6 Hz, 1 H), 7.24 (dt, J = 0.9 Hz, J = 7.3 Hz, 1 H), 7.16 (d, J = 7.9 Hz, 1 H), 6.98 (d, J = 8.4 Hz, 2 H), 6.55-6.46 (m, 2 H), 3.83 (td, J = 2.0 Hz, J = 2.0 Hz, J = 14.3 Hz, 1 H), 2.82 (dd, J = 11.1 Hz, J = 14.3 Hz, 1 H), 1.04 (d, J = 6.8 Hz, 3 H), 0.95-0.83 (m, 1 H), 0.49 (dd, J = 12.0 Hz, J = 14.3 Hz, 1 H), 0.30 (s, 3 H), 0.00 (s, 3 H) ppm. ¹³C{¹H} NMR (125) MHz, JMOD, CDCl₃): δ = 154.0 (C), 145.8 (C), 139.8 (C), 135.1 (CH), 130.6 (CH), 129.4 (CH), 127.4 (CH), 125.7 (C), 125.6 (CH), 113.2 (CH), 59.1 (CH₂), 30.0 (CH), 24.2 (CH₂), 22.8 (CH₃), 20.3 (CH₃), -2.6 (CH₃), -2.7 (CH₃) ppm. ²⁹Si{¹H} NMR (99.4 MHz, CDCI₃): δ = -4.5 ppm. GC/MS (EI, 70 eV): m/z (%) = 295 (93) [M]⁺, 280 (59) [C₁₈H₂₂NSi]⁺, 118 (35) [C₈H₈N]⁺, 91 (53) [C₇H₇]⁺. HRMS (EI): calcd. (C₁₉H₂₅NSi) 295.1751, found 295.1748 [M]⁺. IR (ATR, neat): λ^{-1} = 3064, 3009, 2948, 2917, 2882, 1617, 1584, 1561, 1511, 1467, 1437, 1369, 1347, 1319, 1286, 1252, 1208, 1188, 1164, 1127, 1085, 1026, 867, 825, 790, 740, 704, 670, 632 cm⁻¹. Colorless crystals suitable for single-crystal X-ray analysis^[18] were obtained by crystallization from CH₂Cl₂ at room temperature.

Acknowledgements

We thank the Deutsche Forschungsgemeinschaft for financial support of our research as well as Jessica Reimer, Fenja Martins, and Sonja Timmer for experimental assistance.

Keywords: amination • amines • palladium • silanes • titanium

- [1] R. Tacke, *Chem. Unserer Zeit* **1980**, *14*, 197-207.
- [2] M. G. Voronkov, E. Lukevitz, *Russ. Chem. Rev.* **1969**, *38*, 975-986.
- [3] For reviews on organosilicon compounds with medicinal applications, see: a) J. S. Mills, G. A. Showell, *Expert Opin. Investig. Drugs* 2004, *13*, 1149-1157; b) A.K. Franz, S. O. Wilson, *J. Med. Chem.* 2013, *56*, 388-405.
- [4] For selected examples of the synthesis of new organosilanes, see: a) R. Tacke, H. Linoh, H. Zilch, J. Wess, U. Moser, E. Mutschler, G. Lambrecht, Liebigs Ann. Chem. 1985, 2223-2228; b) R. Tacke, K. Mahner, C. Strohmann, B. Forth, E. Mutschler, T. Friebe, G. Lambrecht, J. Organomet. Chem. 1991, 417, 339-353; c) R. Tacke, T. Heinrich, R. Bertermann, C. Burschka, A. Hamacher, M. U. Kassack, Organometallics 2004, 23, 4468-4477; d) G. Liu, S. M. Sieburth, Org. Lett. 2005, 7, 665-668; e) J. O. Daiss, C. Burschka, J. S. Mills, J. G. Montana, G. A. Showell, I. Fleming, C. Gaudon, D. Ivanova, H. Gronemeyer, R. Tacke, Organometallics 2005, 24, 3192-3199; f) J. O. Daiss, C. Burschka, J. S. Mills, J. G. Montana, G. A. Showell, J. B. H. Warneck, R. Tacke, Organometallics 2006, 25, 1188-1198; g) G. A. Showell, M. J. Barnes, J. O. Daiss, J. S. Mills, J. G. Montana, R. Tacke, J. B. Warneck, Bioorg. Med. Chem. Lett. 2006, 16, 2555-2558; h) M. W. Büttner, M. Penka, L. Doszczak, P. Kraft, R. Tacke, Organometallics 2007, 26, 1295-1298; i) R. Tacke, B. Nguyen, C. Burschka, W. P. Lippert, A. Hamacher, C. Urban, M. U. Kassack, Organometallics 2010, 29, 1652-1660; j) S. Dörrich, S. Falgner, S. Schweeberg, C. Burschka, P. Brodin, B. M. Wissing, B. Basta, P. Schell, U. Bauer, R. Tacke, Organometallics 2012, 31, 5903-5917; k) M. Geyer, J. A. Baus, O. Fjellstrom, E. Wellner, L. Gustafsson, R. Tacke, ChemMedChem 2015, 10. 2063-2070.
- J. C. Venter, L. C. Harrison in *Receptor Biochemistry and Methodology*, *Vol. 5* (Eds.: R. W. Olsen, J. C. Venter), Alan R. Liss, New York, 1986.
- [6] E. Beubler, Kompendium der Pharmakologie, 3. Auflage, Springer-Verlag, Wien, 2011.

- [7] M. Weers, L. H. Lühning, V. Lührs, C. Brahms, S. Doye, Chem. Eur. J. 10.1002/chem.201604561.
- [8] For reviews on the hydroaminoalkylation of alkenes, see: a) P. W.
 Roesky, Angew. Chem. 2009, 121, 4988-4991; Angew. Chem. Int. Ed.
 2009, 48, 4892-4894; b) T.-Q. He, X.-J. Zheng, H. Cai and Z.-L. Xue,
 Chin. J. Inorg. Chem. 2014, 30, 53–61; c) E. Chong, P. Garcia, L. L.
 Schafer, Synthesis 2014, 46, 2884-2896.
- For examples of titanium-catalyzed hydroaminoalkylation reactions of [9] alkenes, see: a) C. Müller, W. Saak, S. Doye, Eur. J. Org. Chem. 2008, 2731-2739; b) R. Kubiak, I. Prochnow, S. Doye, Angew. Chem. 2009, 121, 1173-1176; Angew. Chem. Int. Ed. 2009, 48, 1153-1156; c) I. Prochnow, R. Kubiak, O. N. Frey, R. Beckhaus, S. Doye, ChemCatChem 2009, 1, 162-172; d) R. Kubiak, I. Prochnow, S. Doye, Angew. Chem. 2010, 122, 2683-2686; Angew. Chem. Int. Ed. 2010, 49, 2626-2629; e) I. Prochnow, P. Zark, T. Müller, S. Doye, Angew. Chem. 2011, 123, 6525-6529; Angew. Chem. Int. Ed. 2011, 50, 6401-6405; f) D. Jaspers, W. Saak, S. Doye, Synlett 2012, 23, 2098-2102; g) J. Dörfler, S. Doye, Angew. Chem. 2013, 125, 1851-1854; Angew. Chem. Int. Ed. 2013, 52, 1806-1809; h) T. Preuß, W. Saak, S. Doye, Chem. Eur. J. 2013, 19, 3833-3837; i) E. Chong, L. L. Schafer, Org. Lett. 2013, 15, 6002-6005; j) J. Dörfler, T. Preuß, A. Schischko, M. Schmidtmann, S. Doye, Angew. Chem. 2014, 126, 8052-8056; Angew. Chem. Int. Ed. 2014, 53, 7918-7922; k) J. Dörfler, T. Preuß, C. Brahms, D. Scheuer, S. Doye, Dalton Trans. 2015, 44, 12149-12168; I) J. Dörfler, B. Bytyqi, S. Hüller, N. M. Mann, C. Brahms, M. Schmidtmann, S. Doye, Adv. Synth. Catal. 2015, 357, 2265-2276; m) L. H. Lühning, C. Brahms, J. P. Nimoth, M. Schmidtmann, S. Doye, Z. Anorg. Allg. Chem. 2015, 641, 2071-2082.
- [10] For reviews on the Buchwald-Hartwig amination, see: a) J. F. Hartwig, Nature 2008, 455, 314-322; b) D. S. Surry, S. L. Buchwald, Angew. Chem. 2008, 120, 6438-6461; Angew. Chem. Int. Ed. 2008, 47, 6338-6361; c) B. Schlummer, U. Scholz, Adv. Synth. Catal. 2004, 346, 1599-1626; d) R. Elkema, H. L. Anderson, Macromolecules 2008, 41, 9930-9933.
- [11] Z. Zhang, J.-D. Hamel, L. L. Schafer, Chem. Eur. J. 2013, 19, 8751-8754.
- [12] S. V. Kirpichenko, A. T. Abrosimova, A. I. Albanov, M. G. Voronkov, Russ. J. Gen. Chem. 2001, 71, 1874-1878.
- [13] M. Geyer, O. Karlsson, J. A. Baus, E. Wellner, R. Tacke, J. Org. Chem. 2015, 80, 5804-5811.
- [14] a) G. Wang, Y. Tang, Y. Zhang, X. Liu, L. Lin, X. Feng. *Chem. Eur. J.* **2017**, 23, DOI: 10.1002/chem.201605127; b) V. Corti, P. Camarero Gonzalez, J. Febvay, L. Caruana, A. Mazzanti, M. Fochi, L. Bernardi, *Eur. J. Org. Chem* **2017**, DOI: 10.1002/ejoc.201601364.
- [15] a) S. Shiratori, S. Yasuike, J. Kurita, T. Tsuchiya, *Chem. Pharm. Bull.* **1994**, *42*, 2441-2448; b) S. Yasuike, S. Shiratori, J. Kurita, T. Tsuchiya, *Chem. Pharm. Bull.* **1999**, *47*, 1108-1114.
- For examples of Group 5 metal-catalyzed hydroaminoalkylation [16] reactions of alkenes, see: a) M. G. Clerici, F. Maspero, Synthesis 1980, 305-306; b) W. A. Nugent, D. W. Ovenall, S. J. Holmes, Organometallics 1983, 2, 161-162; c) S. B. Herzon, J. F. Hartwig, J. Am Chem. Soc. 2007, 129, 6690-6691; d) S. B. Herzon, J. F. Hartwig, J. Am. Chem. Soc. 2008, 130, 14940-14941; e) P. Eisenberger, R. O. Ayinla, J. M. P. Lauzon, L. L. Schafer, Angew. Chem. 2009, 121, 8511-8515; Angew. Chem. Int. Ed. 2009, 48, 8361-8365; f) P. Eisenberger, L. L. Schafer, Pure Appl. Chem. 2010, 82, 1503-1515; g) G. Zi, F. Zhang, H. Song, Chem. Commun. 2010, 46, 6296-6298; h) A. L. Reznichenko, T. J. Emge, S. Audörsch, E. G. Klauber, K. C. Hultzsch, B. Schmidt, Organometallics 2011, 30, 921-924; i) A. L. Reznichenko, K. C. Hultzsch, J. Am. Chem. Soc. 2012, 134, 3300-3311; j) P. Garcia, Y. Y. Lau, M. R. Perry, L. L. Schafer, Angew. Chem. 2013, 125, 9314-9318; Angew. Chem. Int. Ed. 2013, 52, 9144-9148; k) J. Dörfler, S. Doye, Eur. J. Org. Chem. 2014, 2790-2797; I) E. Chong, J. W. Brandt, L. L. Schafer, J. Am. Chem. Soc. 2014, 136, 10898-10901.
- [17] T. Elkin, N. V. Kulkarni, B. Tumanskii, M. Botoshansky, L. J. W. Shimon, M. S. Eisen, Organometalics 2013, 32, 6337-6352.

- [18] a) V. Peesapati, U. N. Rao, R. A. Pethrick, *J. Ind. Chem. Soc.* **1991**, *68*, 389-392; b) M. Tominaga, H. Masu, K. Katagiri, T. Kato, I. Azumaya, Org. Lett. **2005**, *7*, 3785-3787; c) Z. Zhang, J.-D. Hamel, L. L. Schafer, *Chem. Eur. J.* **2013**, *19*, 8751-8754.
- [19] Compound **26**: Colorless crystals, dimensions $0.380 \times 0.180 \times 0.080$ mm³, orthorhombic space group *Pca2*₁, unit cell dimensions *a* = 25.9786(6) Å, *b* = 10.6771(2) Å, *c* = 12.2213(3) Å, *V* = 3389.90(13) Å³, Z = 8, $\rho = 1.158$ Mg/m³, $\Theta_{max} = 32.029^{\circ}$, $\mu = 0.133$ mm⁻¹, radiation MoK_{a1}, $\lambda = 0.71073$ Å, ϕ and ω -scans with Bruker KAPPA APEX-II CCD at T = 100(2) K, 122891 reflections measured, 11800 unique [*R*_{int} = 0.0510], 10371 observed [*I*>2 σ (*I*)], an absorption correction was performed based on symmetry related measurements with SADABS (G. M. Sheldrick, University of Göttingen, Germany, 2014), *T*_{min} = 0.9192, *T*_{max} = 1.0000, the structure was solved by direct methods with SHELXS and refined against *P*² employing a full-matrix least-squares algorithm with SHELXL (G. M. Sheldrick, Acta Crystallogr. Sect. C 2015, 71, 3-8), the structure has been refined as a racemic twin (0.68 : 0.32), two molecules are present in the asymmetric unit, both of them showing

whole molecules disorder (0.92 : 0.08), the minor sites were restraint to be equal to the major sites using the SAME instruction within SHELXL, 557 parameters refined, 115 restraints, non H atoms of the major sites were refined anisotropically, those of the minor sites isotropically, hydrogen atoms of the major sites were located from the difference Fourier maps but subsequently fixed to geometric positions using appropriate riding models, final residual values $R_1 = 0.0404$, $wR_2 = 0.1017$ for observed reflections and $R_1 = 0.0499$, $wR_2 = 0.1086$ for all reflections, goodness of fit 1.049, largest diff. peak, hole 0.455 and -0.210 e Å⁻³. CCDC 1511412 contains the supplementary crystallographic data for compound **26**. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

- [20] L. H. Lühning, M. Rosien, S. Doye, Synlett 2017, 28, manuscript in preparation.
- [21] For experimental details, see the Supporting Information.

WILEY-VCH

Entry for the Table of Contents

FULL PAPER

FULL PAPER

